Willingdon Wealth Management boosted its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 4.9% in the 2nd quarter, Holdings Channel reports. The firm owned 21,439 shares of the medical instruments supplier’s stock after buying an additional 995 shares during the period. Becton Dickinson and accounts for about 1.3% of Willingdon Wealth Management’s holdings, making the stock its 25th largest position. Willingdon Wealth Management’s holdings in Becton Dickinson and were worth $5,403,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Becton Dickinson and by 5.0% in the 1st quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after acquiring an additional 842,590 shares during the last quarter. Ronna Sue Cohen increased its position in Becton Dickinson and by 24,129.0% during the 1st quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock valued at $5,734,000 after purchasing an additional 5,710,365 shares during the period. JPMorgan Chase & Co. increased its position in Becton Dickinson and by 10.4% during the 1st quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock valued at $1,103,526,000 after purchasing an additional 416,459 shares during the period. Fundsmith LLP increased its position in Becton Dickinson and by 0.9% during the 1st quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock valued at $941,772,000 after purchasing an additional 35,453 shares during the period. Finally, Northern Trust Corp increased its position in Becton Dickinson and by 0.7% during the 1st quarter. Northern Trust Corp now owns 3,223,811 shares of the medical instruments supplier’s stock valued at $805,082,000 after purchasing an additional 23,645 shares during the period. Hedge funds and other institutional investors own 85.07% of the company’s stock.
In other news, EVP Samrat S. Khichi sold 16,085 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the completion of the sale, the executive vice president now owns 12,608 shares of the company’s stock, valued at $2,958,845.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Patrick Kaltenbach sold 191 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $241.03, for a total transaction of $46,036.73. Following the transaction, the executive vice president now directly owns 19,072 shares in the company, valued at approximately $4,596,924.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,529 shares of company stock valued at $5,836,116. Company insiders own 0.12% of the company’s stock.
Shares of Becton Dickinson and stock traded up $4.19 on Tuesday, reaching $253.34. The stock had a trading volume of 776,439 shares, compared to its average volume of 1,066,327. The firm’s 50 day moving average price is $251.93. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87. The stock has a market cap of $68.66 billion, a PE ratio of 23.01, a P/E/G ratio of 1.85 and a beta of 1.11.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The firm had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the previous year, the firm earned $2.91 EPS. The company’s quarterly revenue was up 1.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.22%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s payout ratio is 27.97%.
A number of research analysts have commented on BDX shares. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Wells Fargo & Co cut their target price on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a research report on Monday, May 13th. Raymond James raised their target price on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research report on Friday, June 28th. Finally, KeyCorp reissued an “overweight” rating and set a $262.00 target price (down previously from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and has an average rating of “Buy” and an average target price of $264.27.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
See Also: Quiet Period Expirations
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.